Letters
NICE’s end of life decision making scheme
Analysis of the impact of extending end of life treatments should be treated with caution
BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3249 (Published 24 May 2013) Cite this as: BMJ 2013;346:f3249
- Paul Catchpole, director1
- 1Association of the British Pharmaceutical Industry, London SW1E 6QT, UK
- pressoffice{at}abpi.org.uk
Collins and Latimer recently estimated the effect on the NHS of the supplementary advice on life extending end of life treatments introduced by the National Institute for Health and Care (formerly Clinical) Excellence (NICE) in 2009.1 2 Their study shows how NICE’s cost effectiveness threshold should work in …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.